Live Breaking News & Updates on Ev 302 Keynote A39 Study

Stay updated with breaking news from Ev 302 keynote a39 study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Japanese Approval Sought for Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

A sNDA seeking approval of enfortumab vedotin plus pembrolizumab for first-line use in patients with urothelial cancer has been submitted to Japan’s MHLW. ....

European Medicines Agency , Astellas Pharma Inc , Japan Ministry Of Health , Medicines Agency , Enfortumab Vedotin , Urothelial Cancer , Supplemental New Drug Application , Ministry Of Health , End Welfare , Ev 302 Keynote A39 Study ,